Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Nina Goodheart Medtronic to retire

Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement. 

Interventional cardiologists take on angiography-derived physiology in new expert opinion

ADP offers care teams multiple benefits not seen with traditional wire-based physiologic assessments. A roundtable of 17 expert clinicians discussed the topic at length, and their findings were used to develop a new manuscript published in JSCAI.

Vinay Badhwar MD WVU

Pioneer heart surgeon Vinay Badhwar elected STS president

Badhwar is a longtime STS member and world leader in robotic technologies. In fact, he and his team recently launched a 40-part video series to help teach other clinicians about robotic-assisted cardiac surgery.

The Impella RP with SmartAssist. Image courtesy of Johnson & Johnson MedTech.

FDA warns that Johnson & Johnson heart pump sensors may malfunction—22 injuries reported

There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

artificial intelligence money finance acquisition

Medtronic to acquire AI-enabled FFR specialists CathWorks for up to $585M

Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. 

Thumbnail

Less than 25% of radiology-related NIH grants have been awarded to female researchers

New findings highlight the lingering issue of gender inequity in the field, the effects of which extend well beyond career growth for women. 

New data from the Phase 3 RAPID clinical trial of etripamil, an investigational calcium channel blocker nasal spray, showed positive results in converting paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in the at-home setting. The presentation was featured during a late-breaking clinical trials session at the American Heart Association (AHA) 2022 Scientific Sessions. #AHA22

Nasal spray for paroxysmal supraventricular tachycardia enters US market

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

Men developed CVD earlier than women, according to 35-year CARDIA study

Promoting preventive care among young adult men during critical periods of their life may be the key to reducing rates of cardiovascular disease.